CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a 2-part study evaluating the efficacy and safety of lorundrostat (an aldosterone synthase inhibitor [ASI]) for the treatment of hypertension...
Phase 2
Louisville, Kentucky, United States and 28 other locations
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the cl...
Phase 3
Louisville, Kentucky, United States and 173 other locations
(for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.Parti...
Phase 3
Louisville, Kentucky, United States and 943 other locations
of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/ ...
Phase 3
Louisville, Kentucky, United States and 348 other locations
The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA...
Phase 3
Louisville, Kentucky, United States and 135 other locations
The primary study objective is to evaluate the benefit of the Sirolimus eluting Collagen implant (SeCI; Sirogen), a single dose prophylactic treatmen...
Phase 3
Louisville, Kentucky, United States and 22 other locations
This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month...
Phase 2
Jeffersonville, Indiana, United States and 16 other locations
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...
Phase 3
Louisville, Kentucky, United States and 390 other locations
The objectives of this study are to evaluate the safety and efficacy of ravulizumab administered by intravenous (IV) infusion compared to placebo and...
Phase 2
Louisville, Kentucky, United States and 80 other locations
To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blo...
Phase 3
Louisville, Kentucky, United States and 161 other locations
Clinical trials
Research sites
Resources
Legal